Lodoxamide

Summary

Lodoxamide (CHEMBL1201266) is an approved small molecule (ATC S01GX05) targeting GPR35; indicated across 1 condition including eye allergy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01GX05
• Targets: 1 (GPR35)
• Indications: 1 condition
• Chemistry: 311.63 Da · C11H6ClN3O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201266
Name	Lodoxamide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	44564
ATC	S01GX05
Molecular formula	C11H6ClN3O6
Molecular weight	311.63
InChIKey	RVGLGHVJXCETIO-UHFFFAOYSA-N

SMILES: C1=C(C=C(C(=C1NC(=O)C(=O)O)Cl)NC(=O)C(=O)O)C#N

IUPAC name: 2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid

Also known as: Lodoxamida, Lodoxamide, lodoxamide, SID170465346, LODOXAMIDE

Parent form; salt/anhydrous children: CHEMBL1201175, CHEMBL3989725

Patent coverage: 910 distinct patent families (3,857 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GPR35	GPR35	Agonist	9	0.2%	Q9HC97

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: G-protein coupled receptor 35, G-protein coupled receptor 35.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
GPR35	7.39	EC50	41.1	nM	CHEMBL_ACT_25496972
Q9ES90	6.38	EC50	422	nM	CHEMBL_ACT_25496994
GPR35	5.4	EC50	4000	nM	CHEMBL_ACT_18198031

Target pathways

Aggregated over 1 target gene(s): GPR35.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Class A/1 (Rhodopsin-like receptors)	1	GPR35

Dominant GO biological processes

GO term	Targets
monocyte chemotaxis	1
response to ischemia	1
cytoskeleton organization	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
positive regulation of cytosolic calcium ion concentration	1
negative regulation of cardiac muscle cell apoptotic process	1
neutrophil chemotaxis	1
leukocyte adhesion to vascular endothelial cell	1
chemokine-mediated signaling pathway	1
negative regulation of voltage-gated calcium channel activity	1
signal transduction	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye allergy	4	MONDO:0005551	EFO:0005751

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

28 molecules share ≥1 primary target. Top 28 by shared-target count:

Molecule	Source	Status	Shared targets
CROMOLYN	ChEMBL + PubChem	Phase 4 (approved)	GPR35
FUROSEMIDE	ChEMBL + PubChem	Phase 4 (approved)	GPR35
AMLEXANOX	ChEMBL	Phase 4 (approved)	GPR35
APREPITANT	ChEMBL	Phase 4 (approved)	GPR35
CINACALCET	ChEMBL	Phase 4 (approved)	GPR35
DICUMAROL	ChEMBL	Phase 4 (approved)	GPR35
EMETINE	ChEMBL	Phase 4 (approved)	GPR35
ENTACAPONE	ChEMBL	Phase 4 (approved)	GPR35
FLUOXETINE	ChEMBL	Phase 4 (approved)	GPR35
LOPERAMIDE	ChEMBL	Phase 4 (approved)	GPR35
NEFAZODONE	ChEMBL	Phase 4 (approved)	GPR35
PERPHENAZINE	ChEMBL	Phase 4 (approved)	GPR35
PIMAVANSERIN	ChEMBL	Phase 4 (approved)	GPR35
TOLCAPONE	ChEMBL	Phase 4 (approved)	GPR35
VORAPAXAR	ChEMBL	Phase 4 (approved)	GPR35
QUERCETIN	ChEMBL + PubChem	Phase 3 (approved)	GPR35
2,4-DINITROPHENOL	ChEMBL	Phase 2	GPR35
BAICALEIN	ChEMBL	Phase 2	GPR35
BUFROLIN	ChEMBL	Phase 2	GPR35
BX 471 FREE BASE	ChEMBL	Phase 2	GPR35
ELLAGIC ACID	ChEMBL	Phase 2	GPR35
FORETINIB	ChEMBL	Phase 2	GPR35
LUTEOLIN	ChEMBL	Phase 2	GPR35
NIFLUMIC ACID	ChEMBL	Phase 2	GPR35
NIGULDIPINE	ChEMBL	Phase 2	GPR35
NITECAPONE	ChEMBL	Phase 2	GPR35
ZAPRINAST	ChEMBL	Phase 2	GPR35
Bumetanide	PubChem	Approved	GPR35